NeuMoDx 288 Fully Automated Molecular Diagnostic System

Overview

The NeuMoDx 288 Fully Automated Molecular Diagnostic System is an integrated, walk-away molecular testing platform engineered for high-throughput clinical microbiology and virology laboratories. Built upon a true random-access architecture, it eliminates batch constraints by enabling on-demand sample processing without pre-scheduling or grouping—significantly reducing time-to-result for stat specimens while maintaining full traceability. At its core, the system combines magnetic-bead-based nucleic acid extraction, NeuDry™ dry-reagent stabilization technology, and microfluidic cartridge-based real-time quantitative PCR (qPCR) amplification within a single sealed consumable. This end-to-end workflow—from primary tube to final Ct value—is executed autonomously, minimizing manual intervention and contamination risk. The system adheres to ISO 15189 and CLIA requirements for analytical validity, with thermal performance validated per ISO 13485 Annex A for diagnostic device reliability.

Key Features

• True random-access operation: Process individual samples at any time without waiting for batch completion—ideal for emergency testing and mixed-workload environments.
• NeuDry™ dry-reagent technology: Pre-dispensed, lyophilized reagents on magnetic beads ensure extended shelf life (>12 months at 2–8°C), eliminate cold-chain dependency, and reduce pipetting variability.
• Microfluidic single-use cartridge: Integrates lysis, binding, washing, elution, reverse transcription (if RNA), and qPCR in one closed unit—no open-tube handling, no carryover, and minimal biohazard exposure.
• Flexible sample tube support: Accommodates standard primary collection tubes (11–18 mm diameter, 60–120 mm height), including EDTA, citrate, and heparin tubes—no secondary transfer required.
• 5-plex qPCR detection per reaction: Supports simultaneous detection of up to five targets plus internal control in a 19 µL reaction volume, optimized for multiplex assay development and co-infection screening.
• Silicon-heated thermal module: Delivers ±0.25°C temperature accuracy across all 96 wells, <2.5 sec/°C ramp rate, and <0.3°C well-to-well uniformity—meeting ASTM E2757-21 criteria for thermal validation in diagnostic PCR instruments.

Sample Compatibility & Compliance

The NeuMoDx 288 accepts native clinical specimens—including nasopharyngeal swabs, bronchoalveolar lavage, urine, whole blood, plasma, and CSF—without preprocessing. Its extraction protocol supports both DNA and RNA targets, with five configurable lysis buffers optimized for diverse matrices (e.g., high-protein, high-mucin, or inhibitor-rich samples). All reagents and cartridges are CE-IVDR certified (Class D) and manufactured under QIAGEN’s ISO 13485:2016 quality management system. The platform meets EU IVDR Annex I essential requirements for safety, performance, and cybersecurity, and supports laboratory compliance with ISO/IEC 17025:2017 for method validation and ongoing QC monitoring.

Software & Data Management

The NeuMoDx Operating System (v5.2+) provides role-based access control, electronic signature capability, and fully auditable 21 CFR Part 11–compliant audit trails—including user actions, parameter changes, calibration logs, and result modifications. Raw fluorescence data, amplification curves, and Ct values are stored in vendor-neutral .csv and .rdml formats. Integration with LIS/HIS is achieved via ASTM E1384-compliant HL7 v2.5.1 messaging and bidirectional ORU/ACK workflows. Custom assay setup—including extraction duration, lysis temperature, PCR cycling profiles, and multi-target threshold definitions—is managed through a secure, password-protected method editor that enforces version-controlled method archiving.

Applications

The NeuMoDx 288 is deployed globally for routine and emergent infectious disease testing, including respiratory virus panels (SARS-CoV-2, influenza A/B, RSV), sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae), gastrointestinal pathogen detection (Clostridioides difficile toxin B, norovirus, rotavirus), and antimicrobial resistance gene screening (e.g., mecA, vanA/vanB). Its LDT-enabling open architecture permits clinical labs to develop, validate, and deploy in-house assays under CLIA/CAP regulatory frameworks—supported by QIAGEN’s validated assay development kit and technical transfer documentation.

FAQ

Does the NeuMoDx 288 support extraction of both DNA and RNA from the same sample?
Yes—the system allows independent selection of lysis buffer and incubation parameters optimized for either DNA-only, RNA-only, or dual-target workflows.
Can custom qPCR assays be validated and run on this platform?
Yes—its open software architecture enables LDT implementation with full control over primer/probe sequences, cycling conditions, and analysis thresholds.
Is the microfluidic cartridge reusable or single-use?
All cartridges are single-use, factory-sealed, and barcoded for lot traceability; no cleaning or reconditioning is permitted or supported.
How does the system handle internal and external quality controls?
Each run includes mandatory process controls (extraction efficiency, inhibition, amplification fidelity) and optional external QC materials mapped to predefined concentration ranges with automated pass/fail flagging.
What LIS connectivity standards does the NeuMoDx 288 support?
HL7 v2.5.1 (ORU^R01, ACK, ADT^A01), ASTM E1384, and direct database export via ODBC-compliant SQL Server or PostgreSQL interfaces.